#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
“The early signals in CBD research for neurodegenerative conditions like Parkinson’s and Alzheimer’s are worth watching, but we’re still largely in the preclinical and early observational phase. Until we have well-designed randomized controlled trials in human subjects, I counsel my patients that this remains an area of genuine scientific interest rather than established clinical practice.”
💊 While cannabidiol (CBD) shows promise in preclinical and early clinical research for neurodegenerative diseases like Parkinson’s and Alzheimer’s, the evidence base remains preliminary and heterogeneous across studies. Current literature is limited by small sample sizes, variable CBD formulations and dosing regimens, lack of long-term safety data, and difficulty isolating CBD effects from other cannabis constituents or concurrent medications in real-world patient populations. Clinicians should be aware that patients with cognitive decline or movement disorders may be self-treating with CBD products purchased outside regulated channels, which introduces additional concerns about product quality, contamination, and drug interactions. Until robust Phase III trials establish efficacy and optimal dosing, discussing CBD with neurology patients should focus on current evidence limitations while remaining open to evolving research. A practical approach is to document any patient use of CBD, monitor for potential interactions with disease-modifying therapies or sympto
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
